Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Gets Atezolizumab Applications Rolling

This article was originally published in Scrip

Executive Summary

Roche Holding AG is behind Merck & Co. Inc. and Bristol-Myers Squibb Co. in the commercial PD-1/PD-L1 immunotherapy race, but the Swiss company says its answer in the drug class, atezolizumab, has now started out on the regulatory road to approval amid high hopes for its therapeutic potential.

You may also be interested in...



Sweden’s Gesynta ‘Phase IIa Ready’ After Private Placing

Gesynta’s SEK190m ($20m) private placement allows its lead asset to enter Phase IIa studies for treating chronic inflammatory conditions in certain systemic sclerosis patients.

Gene Therapy Firm Freeline Successfully Tops Up Series C

An expanded $120m series C financing will help Freeline advance its lead program in hemophilia B into a pivotal trial next year, CEO Theresa Heggie tells Scrip.

Global ‘Talent Contest’ Seeks To Spur AMR Innovation

Novo Holdings’ REPAIR Impact Fund has opened a global ‘AMR talent contest’ to groups developing new antimicrobial treatments, offering direct investment as the prize.

Topics

UsernamePublicRestriction

Register

LL1132940

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel